Good afternoon :)
Place Order
Add to Watchlist

Ngl Fine Chem Ltd

NGLFINE

Ngl Fine Chem Ltd

NGLFINE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,138 cr, stock is ranked 1,429
High RiskStock is 3.18x as volatile as Nifty
1,872.751.65% (+30.35)
1,872.751.65% (+30.35)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,138 cr, stock is ranked 1,429
High RiskStock is 3.18x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,138 cr, stock is ranked 1,429
High RiskStock is 3.18x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.514.330.09%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

NGL Fine-Chem Limited is manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health.

Investor Presentation

View older 

Nov 11, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.54%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.07% to 0.09%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 15.48%, vs industry avg of 15.27%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue157.29154.74265.99328.18283.61352.82390.31
Raw Materialssubtract65.2971.02102.62172.27118.75173.47321.35
Power & Fuel Costsubtract8.719.999.8515.8618.5323.25
Employee Costsubtract21.1624.0428.0934.8536.8745.12
Selling & Administrative Expensessubtract10.228.0011.628.6911.5514.90
Operating & Other expensessubtract15.5018.8725.6917.6457.4228.20
Depreciation/Amortizationsubtract6.308.118.3310.3711.2911.6411.89
Interest & Other Itemssubtract2.552.632.201.911.831.811.53
Taxes & Other Itemssubtract7.443.7320.8716.706.8713.1114.16
EPS32.5713.5291.8180.7533.1866.8866.98
DPS1.751.751.751.751.751.751.75
Payout ratio0.050.130.020.020.050.030.03

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual Report Unavailable

FY 2021

Annual report

PDF

Investor Presentation

Jun 8PDF
Jun 8PDF
FY 2022

Annual report

PDF

Investor Presentation

Nov 11PDF
Aug 2PDF
FY 2023

Annual report

PDF

Investor Presentation

May 18PDF
Feb 20PDF
Nov 16PDF
Aug 12PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Ngl Fine Chem Ltd27.554.330.09%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare NGLFINE with any stock or ETF
Compare NGLFINE with any stock or ETF
NGLFINE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.74%0.00%0.00%0.02%27.25%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.02%0.04%0.10%0.03%0.02%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Ngl Fine Chem Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0004%0.03%0.03%98/102 (+2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

NGLFINE has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.09%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.95 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 16, 2024

Final
Final | Div/Share: ₹1.75

Dividend/Share

₹1.75

Ex DateEx Date

Aug 16, 2024

Cash Dividend

Ex DateEx DateAug 18, 2023

Final
Final | Div/Share: ₹1.75

Dividend/Share

₹1.75

Ex DateEx Date

Aug 18, 2023

Cash Dividend

Ex DateEx DateJun 22, 2022

Final
Final | Div/Share: ₹1.75

Dividend/Share

₹1.75

Ex DateEx Date

Jun 22, 2022

Cash Dividend

Ex DateEx DateAug 12, 2021

Final
Final | Div/Share: ₹1.75

Dividend/Share

₹1.75

Ex DateEx Date

Aug 12, 2021

Cash Dividend

Ex DateEx DateAug 6, 2020

Final
Final | Div/Share: ₹1.75

Dividend/Share

₹1.75

Ex DateEx Date

Aug 6, 2020

News & Opinions
Corporate
NGL Fine-Chem schedules board meeting

NGL Fine-Chem will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
NGL Fine Chem consolidated net profit rises 8.34% in the June 2024 quarter

Net profit of NGL Fine Chem rose 8.34% to Rs 9.22 crore in the quarter ended June 2024 as against Rs 8.51 crore during the previous quarter ended June 2023. Sales rose 27.74% to Rs 90.75 crore in the quarter ended June 2024 as against Rs 71.04 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales90.7571.04 28 OPM %10.3113.89 - PBDT14.7912.94 14 PBT11.7910.08 17 NP9.228.51 8 Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
NGL Fine Chem standalone net profit rises 0.26% in the June 2024 quarter

Net profit of NGL Fine Chem rose 0.26% to Rs 7.83 crore in the quarter ended June 2024 as against Rs 7.81 crore during the previous quarter ended June 2023. Sales rose 27.38% to Rs 88.03 crore in the quarter ended June 2024 as against Rs 69.11 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales88.0369.11 27 OPM %7.1811.00 - PBDT12.1511.16 9 PBT10.019.16 9 NP7.837.81 0 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
NGL Fine-Chem announces board meeting date

NGL Fine-Chem will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Nucleus Software Exports Ltd leads losers in ‘B’ group

4 months agoBusiness Standard

NGL Fine Chem soars 13% on strong operational performance in Q4

1 year agoMoneycontrol

Biofil Chemicals & Pharmaceuticals Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

NGL Fine Chem consolidated net profit declines 66.43% in the September 2022 quarter

2 years agoBusiness Standard

NGL Fine Chem standalone net profit declines 65.05% in the September 2022 quarter

2 years agoBusiness Standard

NGL Fine Chem standalone net profit declines 45.07% in the March 2022 quarter

2 years agoBusiness Standard